Search results for "Atomoxetine hydrochloride"

showing 3 items of 3 documents

Modulation of high impulsivity and attentional performance in rats by selective direct and indirect dopaminergic and noradrenergic receptor agonists

2011

Rationale Impulsivity is associated with a number of psychiatric disorders, most notably attention deficit/hyperactivity disorder (ADHD). Drugs that augment catecholamine function (e.g. methylphenidate and the selective noradrenaline reuptake inhibitor atomoxetine) have clinical efficacy in ADHD, but their precise mechanism of action is unclear. Objective The objective of this study is to investigate the relative contribution of dopamine (DA) and noradrenaline (NA) to the therapeutic effects of clinically effective drugs in ADHD using rats selected for high impulsivity on the five-choice serial reaction time task (5CSRTT). Methods We examined the effects of direct and indirect DA and NA rec…

MaleImpulsivityQuinpiroleDopamineSerial LearningAtomoxetine HydrochlorideImpulsivityChoice BehaviorPiperazines03 medical and health sciences0302 clinical medicineQuinpiroleDopaminemental disordersAnimals Outbred StrainsReaction TimemedicineAnimalsAttentionOriginal InvestigationPharmacologyPropylaminesMethylphenidateDopaminergicAtomoxetineGBR-12909Adrenergic AgonistsGuanfacineRats030227 psychiatry3. Good healthGuanfacineSumaniroleFive-choice serial reaction time taskAtomoxetine; Dopamine; Five-choice serial reaction time task; GBR-12909; Guanfacine; Impulsivity; Methylphenidate; Noradrenaline; Quinpirole; Sumanirole; Adrenergic Agonists; Animals; Animals Outbred Strains; Atomoxetine Hydrochloride; Attention; Benzimidazoles; Choice Behavior; Dopamine Agonists; Guanfacine; Impulsive Behavior; Male; Methylphenidate; Piperazines; Propylamines; Quinpirole; Rats; Reaction Time; Serial Learning; PharmacologyAnesthesiaDopamine AgonistsImpulsive BehaviorNoradrenalineAtomoxetineMethylphenidateBenzimidazolesmedicine.symptomPsychologyNeuroscience030217 neurology & neurosurgerymedicine.drugAtomoxetine hydrochloride
researchProduct

Efficacy and safety of extended-release guanfacine hydrochloride in children and adolescents with attention-deficit/hyperactivity disorder: A randomi…

2014

AbstractGuanfacine extended-release (GXR), a selective α2A-adrenergic agonist, is a non-stimulant treatment for attention-deficit/hyperactivity disorder (ADHD). This study assessed the efficacy (symptoms and function) and safety of dose-optimized GXR compared with placebo in children and adolescents with ADHD. An atomoxetine (ATX) arm was included to provide reference data against placebo. Patients (6–17 years) were randomized at baseline to dose-optimized GXR (0.05–0.12mg/kg/day – 6–12 years: 1–4mg/day; 13–17 years: 1–7mg/day), ATX (10–100mg/day) or placebo for 4 or 7 weeks. The primary efficacy measure was change from baseline in ADHD Rating Scale version IV (ADHD-RS-IV). Key secondary me…

Malemedicine.medical_specialtyAdolescentClinical NeurologyAtomoxetine HydrochloridePlaceboDouble-Blind MethodRating scaleInternal medicineAdrenergic alpha-2 Receptor AgonistsmedicineHumansAttention deficit hyperactivity disorderPharmacology (medical)FunctionGuanfacine HydrochlorideChildAdverse effectBiological PsychiatryPsychiatric Status Rating ScalesPharmacologyAdrenergic Uptake InhibitorsDose-Response Relationship DrugPropylaminesAtomoxetinemedicine.diseaseGuanfacineGuanfacinePsychiatry and Mental healthAttention-deficit/hyperactivity disorderNeurologyTreatment efficacyAttention Deficit Disorder with HyperactivityDelayed-Action PreparationsAnesthesiaFemaleNeurology (clinical)Safetymedicine.symptomPsychologySomnolencemedicine.drugEuropean Neuropsychopharmacology
researchProduct

Systematic review and exploratory meta-analysis of the efficacy, safety, and biological effects of psychostimulants and atomoxetine in patients with …

2019

ObjectiveOur aim was to summarize the efficacy and safety of atomoxetine, amphetamines, and methylphenidate in schizophrenia.MethodsWe undertook a systematic review, searching PubMed/Scopus/Clinicaltrials.gov for double-blind, randomized, placebo-controlled studies of psychostimulants or atomoxetine in schizophrenia published up to 1 January 2017. A meta-analysis of outcomes reported in two or more studies is presented.ResultsWe included 22 studies investigating therapeutic effects of stimulants (k=14) or measuring symptomatic worsening/relapse prediction after stimulant challenge (k=6). Six studies of these two groups plus one additional study investigated biological effects of psychostimu…

safetymedicine.medical_specialtyPsychosismedicine.medical_treatmentefficacyamphetamineSchizoaffective disorderAtomoxetine Hydrochloridemeta-analysi03 medical and health sciencesExecutive Function0302 clinical medicinesystematic reviewInternal medicinemedicineHumansAttentionAmphetamineProblem Solvingbusiness.industryMethylphenidateAtomoxetineAmphetaminesrelapse predictorstimulantmedicine.disease030227 psychiatryStimulantPsychiatry and Mental healthMemory Short-Termamphetamine atomoxetine efficacy meta-analysis methylphenidate relapse predictor safety schizophrenia stimulants systematicn reviewPsychotic DisordersSchizophreniaMeta-analysisMethylphenidateSchizophreniaNeurology (clinical)businessatomoxetine030217 neurology & neurosurgerymedicine.drugAntipsychotic Agents
researchProduct